Building in genomics? You do not have to navigate it alone.
If you are building in genomics, AI biology, diagnostics, synthetic biology, precision medicine, biodiversity, drug discovery or biodata, you are not just launching another company. You are building inside a shift that will reshape medicine, food, ecosystems, families, markets and regulation.
I work with founders because I understand both sides of this work: the science and the company-building. As a scientist, strategist and serial founder of Relatix Bio and Helminthix, I know what it is like to turn a difficult biological idea into a venture, explain it to investors and partners, and make choices before the market has caught up.
Because the founders who survive contact with reality are the ones who understood the biology’s constraints before they wrote the pitch deck, not after.
Join the launch list and follow the book
Founders often build before the world has language for what they are building.
Genomics founders often have to explain three things at once: the science, the product and why the timing is now. That is hard enough before you add regulation, data governance, clinical evidence, investor expectations, ethics, public trust and the possibility that your work may affect future patients, families, ecosystems or generations.
That is also what makes this field extraordinary. Some of the most important companies of the next few decades will be built by people who can connect biological insight with practical execution, credible storytelling and real responsibility.
How I can help
Strategy and positioning
Clarify what you are really building, who it is for, what makes it defensible, and how to explain it without flattening the science.
Narrative, investors and partners
Shape a story that works for investors, collaborators, boards, scientific partners and non-specialist decision-makers without drifting into hype.
Advisory and board support
Bring scientific, strategic, ethical and market perspective into board discussions, advisory roles, strategic reviews or early venture decisions.
Risk, ethics and responsibility
Pressure-test assumptions around data, regulation, public trust, biological risk, clinical claims, biodiversity, equity and long-term societal impact.
Founder-to-founder, not consultant-to-client.
I know the uncomfortable middle of company-building: the stage where the science is promising, the story is still forming, the product is not yet obvious, and every conversation with an investor, partner or early hire changes what you think you are building.
My work brings together scientific depth, strategic judgement, communication, governance and lived founder experience—including through Relatix Bio and Helminthix—to help ventures make better decisions earlier.
What we might work on together
We might work together on questions like:
- What are you really building?
- What is hype, what is real and what is investable?
- Where is your defensible advantage?
- What should you build first?
- What evidence will matter most?
- How do you explain the science clearly?
- What will investors misunderstand?
- What could regulators, clinicians, partners or the public challenge?
- Where are the ethical or societal risks?
- How do you grow without losing scientific seriousness?
Stay close to the book as it develops
The Genomic Power Shift is also a book about the world founders are helping to create: a world where the language of life becomes readable, programmable, investable and politically consequential.
Join the launch list for occasional notes, essays, sample chapters and publication updates. It is also a useful way to share the book with co-founders, friends, colleagues, team members and investors who need a clear, accessible way into the genomic era.
Want a strategic sounding board?
If you are building something serious in genomics, AI biology, biotech, diagnostics, biodata, health, food, biodiversity or synthetic biology, I would be happy to hear what you are working on. I can help as a consultant, advisor, board member, reviewer, collaborator or strategic sounding board.